SOUTH SAN FRANCISCO, Calif., Aug. 16 Anesiva,Inc. (Nasdaq: ANSV) will announce an encouraging development in the Zingo(TM)development program before the markets open tomorrow. A conference call andlive webcast will be held at 8:30 a.m. Eastern Time tomorrow to discuss theannouncement.
Interested parties can listen to the live audio webcast by dialing800-340-6289 (international dial: 706-634-1538) or by logging on tohttp://www.anesiva.com and going to the Investor Information page. Pleaseconnect to Anesiva's website several minutes prior to the start of theconference call to ensure adequate time for any software download that may benecessary. For those unable to participate via the Internet, a 24-hour replaywill be available for seven days after the call by dialing 800-642-1687(international dial: 706-645-9291) and giving the following pass code:13882358.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to bethe leader in the development and commercialization of novel therapeutictreatments for pain. The company has two drug candidates in development formultiple pain-related indications. A New Drug Application (NDA) has been filedfor the most advanced product, Zingo(TM). The second product in the pipeline,Adlea(TM) (formerly 4975), has been shown to reduce pain after only a singleadministration for weeks to months in multiple settings in numerous mid-stageclinical trials for site-specific, moderate-to-severe pain. Anesiva is basedin South San Francisco, CA. For more information about Anesiva's leadership inthe development of products for pain management, and an overview of theclinical challenges being addressed by its product candidates, go tohttp://www.anesiva.com.
SOURCE Anesiva, Inc.